King Charles III Is Being Treated for Cancer, Will Temporarily Halt Public Duties 

Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
TT

King Charles III Is Being Treated for Cancer, Will Temporarily Halt Public Duties 

Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)
Britain's King Charles leaves the London Clinic after receiving treatment for an enlarged prostate, in London, Britain January 29, 2024. (Reuters)

Britain's King Charles III has been diagnosed with cancer and has begun treatment, Buckingham Palace said Monday. Less than 18 months into his reign, the 75-year-old monarch will suspend public engagements but will continue with state business, and won't be handing over his constitutional roles as head of state.

The palace didn't disclose what form of cancer the king has, but said it's not related to his recent treatment for a benign prostate condition.

The palace said "a separate issue of concern was noted" during Charles' treatment for an enlarged prostate last month, when he spent three nights in a London hospital.

"Diagnostic tests have identified a form of cancer," it said in a statement.

"His Majesty has today commenced a schedule of regular treatments, during which time he has been advised by doctors to postpone public-facing duties," the palace said. "Throughout this period, His Majesty will continue to undertake State business and official paperwork as usual."

The king is being treated as an outpatient, the palace said.

It said Charles, who has generally enjoyed good health, "remains wholly positive about his treatment and looks forward to returning to full public duty as soon as possible."

The palace added that the king "has chosen to share his diagnosis to prevent speculation and in the hope it may assist public understanding for all those around the world who are affected by cancer."

Charles became king in September 2022 when his mother, Queen Elizabeth II, died at the age of 96 after 70 years on the throne.

News of the king's diagnosis comes as his daughter-in-law Kate, Princess of Wales, recovers from abdominal surgery that saw her hospitalized for about two weeks.

Kate is still taking a break from royal duties as she recovers. Her husband, Prince William, who is heir to the throne, also took time off to help look after the couple's three children, but is due to preside over an investiture ceremony at Windsor Castle and a charity dinner on Wednesday.

Charles took the throne intending to preside over a slimmer monarchy with fewer senior royals carrying out ceremonial public duties. But with Charles and Kate both temporarily sidelined, Prince Harry self-exiled to California and Prince Andrew largely banished from view because of his friendship with sex offender Jeffrey Epstein, the royal "Firm" risks becoming severely overstretched.

The king personally called both William and Harry — as well as his siblings Princess Anne, Prince Andrew and Prince Edward — to share news of his health.

Harry, who quit royal duties in 2020, has spoken to his father about the diagnosis and "will be traveling to UK to see His Majesty in the coming days," said the office of Harry and his wife, Meghan.

UK political leaders sent messages of support. Prime Minister Rishi Sunak tweeted: "Wishing His Majesty a full and speedy recovery. I have no doubt he’ll be back to full strength in no time and I know the whole country will be wishing him well."

US President Joe Biden, traveling in Las Vegas on Monday, said he had just learned about Charles’s diagnosis and said he hopes to speak with him, "God willing."

"I’m concerned about him," Biden told reporters.

The president later posted on X, formerly known as Twitter: "Navigating a cancer diagnosis, treatment, and survivorship takes hope and absolute courage. Jill and I join the people of the United Kingdom in praying that His Majesty experiences a swift and full recovery."

Charles departed from royal tradition with his openness about his prostate condition. For centuries Britain's royal family remained tight-lipped about health matters.

When UK monarchs had real power, news of illness was withheld for fear it might weaken their authority. The habit of secrecy lingered after royals became constitutional figureheads.

The British public wasn’t told that Charles’ grandfather, King George VI, had lung cancer before his death in February 1952 at the age of 56, and some historians have claimed that the king himself wasn’t told he was terminally ill.

In the final years of Elizabeth's life, the public was told only that the queen was suffering from "mobility issues." The cause of her death was listed on the death certificate simply as "old age."

Pat Price, founder of the Catch Up With Cancer campaign, said millions shared the "collective concern" for the king's health.

"The king’s openness about his battle with cancer is a powerful reminder that one in two of us may face cancer at some point in our lives," Price said.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”